MAP2K7 and acute myeloid leukemia: Moreover, the combination of AZA/VEN with the MEK inhibitor trametinib, as well as the combination of VEN with the MEK1 inhibitor cobimetinib, showed modest activity in R/R AML, with a response rate of 25% and 18%, respectively, along with substantial toxicity, limiting their clinical use [116,117].